Clinical trials: Next Generation Sequencing
Periodontitis, Peri-implant Mucositis
Biological Responses Affecting Early-stage Dental Implant Placement in Patients With History of Periodontitis
This prospective parallel, double-blind, four-arm randomised controlled clinical study is planned to assess the difference in the level of the inflammatory biomarkers expressed following the placement of the first dental implant…
- Conditions
- Periodontitis, Peri-implant Mucositis, Peri-Implantitis
- Trial name
- NCT05834946
- Testing
- Megagen implant placement, Biomate-Swiss implant
- Where
- Malaysia
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Teratozoospermia, Sperm DNA Fragmentation
PGT-A Evaluates Advanced Sperm Selection in Embryos From High Teratozoospermia Males
In this study of 264 couples, sperm selection techniques in males with high teratozoospermia index and sperm DNA fragmentation significantly increased fertilization, blastocyst development rates, and maintained comparable embryo…
- Conditions
- Teratozoospermia, Sperm DNA Fragmentation, Infertility
- Trial name
- NCT06231589
- Testing
- Sperm Selection
- Where
- Egypt
- Volunteers
- 264 people
- Sponsor
- Ganin Fertility Center
Hematologic Malignancies
Matching Patients With Hematologic Malignancy to Adequate Clinical Trials
A molecular profile of a patient with hematologic malignancy, for whom standard-of-care had failed, is identified using next generation sequencing.
- Trial name
- NCT02758080
- Testing
- Matching on the basis of molecular analysis, Matching on the basis of physician's choice
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
Breast Cancer, Metastatic Breast Cancer
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
MELODY is a prospective, single-arm phase II study introducing routine liquid-biopsy next-generation sequencing for patients with advanced or unresectable breast cancer in Ireland.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Trial name
- MELODY (NCT07893730)
- Testing
- Liquid biopsy next generation sequencing
- Volunteers
- 50 people
- Sponsor
- University College Cork
Invasive Pulmonary Fungal Disease
Blood mNGS for Diagnosing Invasive Pulmonary Fungal Disease in Hematologic Patients
The goal of this clinical trial is to learn whether a blood test called metagenomic next-generation sequencing (mNGS) can help diagnose invasive pulmonary fungal disease in patients with blood disorders.
- Trial name
- NCT07511595
- Testing
- Blood microbial metagenomic next-generation sequencing (mNGS)
- Volunteers
- 1,000 people
- Sponsor
- Peking University People's Hospital
NSCLC
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
This multicenter, retrospective cohort study plans to enroll patients with lung adenocarcinoma who received neoadjuvant immunotherapy prior to surgery and did not achieve pathological complete response (non-pCR) upon…
- Trial name
- NCT07179445
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Neoplasms, Carcinoma Non-small-cell Lung
A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing
The investigators are doing this research to see if they can use small tissue samples or fluid to develop a test that will determine if the tissue samples are related or not related to each other.
- Trial name
- NCT02705404
- Testing
- Multifocal Tissue Banking
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Plasma Cell Disorder
Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand.
- Trial name
- genetics MM (NCT06330896)
- Volunteers
- 498 people
- Sponsor
- Siriraj Hospital
Lung Cancer, Brain Metastases
A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases
Primary lung cancer is one of the most common malignancies in China, with 57 percent of patients being diagnosed at advanced stage. At present, advanced lung cancer has entered the era of precise treatment.
- Conditions
- Lung Cancer, Brain Metastases, Cerebrospinal Fluid, Next-generation Sequencing
- Trial name
- NCT03257735
- Testing
- next-generation sequencing
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Rare Diseases, Genetic Predisposition
Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases
The DiRiP study will enroll patients (n = 3500) with unclear rare diseases and suspected genetic reasons. In group 1 (n = 500) subjects are clinically characterized in the context of outpatient/ inpatient standard care at the UKT…
- Trial name
- DiRiP-RD (NCT03491280)
- Testing
- NGS Diagnostic
- Where
- Germany
- Volunteers
- 5,500 people
- Sponsor
- University Hospital Tuebingen
Antimicrobial Drug Resistance, High-Throughput Nucleotide Sequencing
The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens
This observational study is to learn about the predictive value of targeted next-generation sequencing(tNGS) in pathogen resistance phenotype of patients with lower respiratory tract infection ,by detecting…
- Trial name
- NCT07035535
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-small Cell Lung Cancer Stage I
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
CtDNA detection is a noninvasive detection method, and the second generation of high-throughput gene sequencing (NGS) is an important means of detecting ctDNA, which can detect trace ctDNA from smaller plasma samples.
- Trial name
- NCT03172156
- Testing
- ctDNA detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Intellectual Disability, Congenital Abnormalities
Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
Apparently balanced chromosomal rearrangement (ABCR) associated with an abnormal phenotype is a rare but problematic event. It occurs in 6% of de novo reciprocal translocations and 9% of de novo inversions.
- Trial name
- ANI (NCT02451761)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Hospices Civils de Lyon
Severe Acute Respiratory Infection, Community-acquired Pneumonia
mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients
Severe Community-acquired pneumonia (SCAP) is a leading global infectious cause of intensive care unit (ICU) admission (approximately 20%-30%), and the primary reason of mortality and morbidity in immunocompromised patients.
- Conditions
- Severe Acute Respiratory Infection, Community-acquired Pneumonia, Respiratory Tract Infections, Pneumonia
- Trial name
- MATESHIP (NCT05290454)
- Testing
- mNGS-guided treatment
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Qilu Hospital of Shandong University
Colorectal Carcinoma, Soft Tissue Sarcoma
Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study
Next Generation Sequencing in cancer: a feasibility study in France to assess sample circuit and to perform analyzes within a limited time.
- Trial name
- MULTIPLI-0 (NCT03546127)
- Testing
- Next Generation Sequencing (NGS): exome, RNA seq
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Fractures, Bone, Infections
Clinical Metagenomic of Post-traumatic Infections
Treatment of fracture related infection is challenging and often lead to failure in such situation that carry a high health cost burden.
- Trial name
- METADIAG (NCT05770856)
- Testing
- Metagenomic sequencing
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Breast Neoplasm Female, Therapeutics
Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer
To determine the landscape of gene mutation before and after endocrine therapy, to search for molecular markers of endocrine therapy efficacy, and to explore the clinical value of using NGS detection of ctDNA to guide precise…
- Conditions
- Breast Neoplasm Female, Therapeutics, Mutation
- Trial name
- NCT03786575
- Testing
- Next Generation Sequencing (NGS) detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College
Solid Tumors, Metastatic Disease
CPCT-02 Biopsy Protocol
A major challenge for researchers in cancer care is to expedite the development of new therapeutics and the Center for Personalized Cancer Treatment (a collaboration of the Dept.
- Trial name
- CPCT-02 (NCT01855477)
- Testing
- Histological biopsy procedure
- Where
- Netherlands
- Volunteers
- 6,927 people
- Sponsor
- Foundation CPCT
Subfertility
Preimplantation Genetic Testing for Aneuploidy of Polar Bodies
This study intends to randomly group the patients with advanced maternal age and poor ovarian response, and the study group will undergo polar body biopsy, and the next-generation sequencing(NGS) technology will be used to…
- Trial name
- NCT04538560
- Testing
- polar body biopsy
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Reproductive & Genetic Hospital of CITIC-Xiangya
Cancer
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
- Trial name
- NCT06207032
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Tempus AI